Merve Cansu Polat, Saniye Mertek, Zeynep Birsin Özçakar, Elif Çelikel, Fatma Aydın, Zahide Ekici Tekin, Atilla Halil Elhan, Banu Çelikel Acar, Nilgün Çakar
OBJECTIVES: To evaluate adverse events (AEs) in pediatric patients with rheumatologic diseases being treated with approved or off-label biologic agents (BAs). METHODS: This observational, retrospective, multicenter study was conducted from 2010 to 2022 in patients under 18 years of age with rheumatic diseases who were receiving interleukin-1 antibodies (Anti-IL1), interleukin-6 antibodies (Anti-IL6), and tumor necrosis factor alpha inhibitors (anti-TNF). Efficacy, AEs, and timing of AEs were collected from electronic medical records...
February 28, 2024: Postgraduate Medicine